ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK to boost shingles vaccine production

by Ryan Cross
April 26, 2019 | APPEARED IN VOLUME 97, ISSUE 17

 

GlaxoSmithKline is spending $100 million to increase production at its vaccine facility in Hamilton, Montana. The site makes adjuvants—immune-stimulating molecules—for vaccines, including Shingrix, designed to prevent shingles in adults aged 50 and older. GSK hasn’t been able to keep up with demand since Shingrix was approved in the US in 2017. The Shingrix adjuvant contains a saponin molecule extracted from the Chilean soap bark tree.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment